Will the biotech need to find a suitor after the halting of a once-promising development program?
This stock offers exposure to two attractive market sectors in one company.
The heart pill could be a blockbuster product.
After a huge fraud settlement, the drug company has new management and a promising future.
Stocks of both companies doubled this year on hope their drugs will be approved for sale in the US.
Vivus becomes the second pharma this year approved to sell a weight-loss treatment.
The manufacturer of permanent birth control system announced its next-generation procedure.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
Remember when real estate was so hot there were homebuyer lotteries and bidding wars? And people so desperate to buy that they'd make an offer sight-unseen? In some markets, they're back.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.